Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer and his cousin Charles F. Erhart.
Company profile
Ticker
PFE
Exchange
Website
CEO
Albert Bourla
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
356 Royalty Inc. • Agouron Pharmaceuticals, LLC • AH Robins LLC • AHP Manufacturing B.V. • Alpharma Pharmaceuticals LLC • American Food Industries LLC • Amplyx Pharmaceuticals, Inc. • Anacor Pharmaceuticals, LLC • Arena Pharmaceuticals Canada Holdings, L.P. • Arena Pharmaceuticals Development GmbH ...
PFE stock data
Latest filings (excl ownership)
PX14A6G
Letter to shareholders
16 Apr 24
DEFA14A
Additional proxy soliciting materials
11 Apr 24
DEFA14A
Additional proxy soliciting materials
11 Apr 24
DEFA14A
Additional proxy soliciting materials
11 Apr 24
DEFA14A
Additional proxy soliciting materials
9 Apr 24
DEFA14A
Additional proxy soliciting materials
28 Mar 24
DEFA14A
Additional proxy soliciting materials
28 Mar 24
ARS
2023 FY
Annual report to shareholders
14 Mar 24
DEFA14A
Additional proxy soliciting materials
14 Mar 24
DEF 14A
Definitive proxy
14 Mar 24
Transcripts
PFE
Earnings call transcript
2023 Q4
30 Jan 24
PFE
Earnings call transcript
2023 Q3
31 Oct 23
PFE
Earnings call transcript
2023 Q2
1 Aug 23
PFE
Earnings call transcript
2023 Q1
2 May 23
PFE
Earnings call transcript
2022 Q4
31 Jan 23
PFE
Earnings call transcript
2022 Q3
1 Nov 22
PFE
Earnings call transcript
2022 Q2
28 Jul 22
PFE
Earnings call transcript
2022 Q1
3 May 22
PFE
Earnings call transcript
2021 Q4
8 Feb 22
PFE
Earnings call transcript
2021 Q3
3 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Oct 23 | Jul 23 | Apr 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 3.23 bn | 3.23 bn | 3.23 bn | 3.23 bn | 3.23 bn | 3.23 bn |
Cash burn (monthly) | (no burn) | (no burn) | 1.12 bn | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | n/a | n/a | 7.69 bn | n/a | n/a | n/a |
Cash remaining | n/a | n/a | -4.45 bn | n/a | n/a | n/a |
Runway (months of cash) | n/a | n/a | -4.0 | n/a | n/a | n/a |
Institutional ownership, Q4 2023
48.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2453 |
Opened positions | 241 |
Closed positions | 642 |
Increased positions | 710 |
Reduced positions | 1358 |
13F shares | Current |
---|---|
Total value | 74.73 tn |
Total shares | 2.75 bn |
Total puts | 17.83 mm |
Total calls | 33.89 mm |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 506.52 mm | $14.58 tn |
STT State Street | 287.48 mm | $8.28 tn |
Wellington Management | 239.21 mm | $6.89 tn |
Capital World Investors | 173.39 mm | $4.99 tn |
Charles Schwab Investment Management | 104.25 mm | $2.99 tn |
MS Morgan Stanley | 82.11 mm | $2.36 tn |
Massachusetts Financial Services | 68.51 mm | $1.97 tn |
NTRS Northern Trust | 59.81 mm | $1.72 tn |
LGEN Legal & General | 49.62 mm | $1.43 tn |
BK Bank Of New York Mellon | 44.09 mm | $1.27 tn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
25 Apr 24 | Blaylock Ronald E | Phantom Stock Units Common Stock | Grant | Acquire A | No | No | 25.26 | 8,115.598 | 205.00 k | 58,627.024 |
25 Apr 24 | Narayen Shantanu | Phantom Stock Units Common Stock | Grant | Acquire A | No | No | 25.26 | 8,115.598 | 205.00 k | 142,517.615 |
25 Apr 24 | Littman Dan R. | Phantom Stock Units Common Stock | Grant | Acquire A | No | No | 25.26 | 8,115.598 | 205.00 k | 50,295.479 |
25 Apr 24 | Susan Hockfield | Phantom Stock Units Common Stock | Grant | Acquire A | No | No | 25.26 | 8,115.598 | 205.00 k | 31,187.802 |
25 Apr 24 | Gottlieb Scott | Phantom Stock Units Common Stock | Grant | Acquire A | No | No | 25.26 | 8,115.598 | 205.00 k | 34,886.291 |
News
COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle
26 Apr 24
FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia
26 Apr 24
Pfizer's Options: A Look at What the Big Money is Thinking
26 Apr 24
Pfizer Says U.S. FDA Approved Company's BEQVEZ (fidanacogene elaparvovec-dzkt), A One-Time Gene Therapy For Adults With Hemophilia B; Company Now Plans Launching An Innovative Warranty Program Based On Durability Of Patient Response To Treatment
26 Apr 24
Bristol-Myers Q1 Loss Narrower Than Expected, Sales Beat
25 Apr 24
Press releases
U.S. FDA Approves Pfizer's BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
26 Apr 24
Pfizer Declares Second-Quarter 2024 Dividend
24 Apr 24
Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25
11 Apr 24
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
9 Apr 24
ALTIVIA Appoints Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager
8 Apr 24